Steadybase.

Sinovac Biotech Ltd.

Website Investor relations
  • SVA ยท Nasdaq
  • Pharmaceutical Preparations
  • Beijing, China
  • 2,602 employees
  • CIK 0001084201

Updated from SEC filings through

Top things to know

Executives

Sinovac Biotech Ltd is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Beijing, China. It trades as SVA on Nasdaq. Revenue was $386M in the fiscal year ending December 31, 2025, +6.8% from the year before. It reported about 2,602 employees. Yin Weidong is Chief Executive Officer.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue $386M
20-F, 2026-06-05
$361M
20-F, 2026-06-05
$470M
20-F, 2026-06-05
$1.5B
20-F, 2026-04-30
$19.4B
20-F, 2026-04-30
Operating income -$490M
20-F, 2026-06-05
-$506M
20-F, 2026-06-05
-$714M
20-F, 2026-06-05
-$509M
20-F, 2026-04-30
$17.6B
20-F, 2026-04-30
SG&A $333M
20-F, 2026-06-05
$421M
20-F, 2026-06-05
$598M
20-F, 2026-06-05
$836M
20-F, 2026-04-30
$602M
20-F, 2026-04-30
Net income -$199M
20-F, 2026-06-05
$40.7M
20-F, 2026-06-05
-$13.5M
20-F, 2026-04-30
$14.5M
20-F, 2026-04-30
$8.1B
20-F, 2026-04-30

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Yin Weidong
Chairman, President & CEO at SINOVAC BIOTECH LTD.
Chief Executive Officer Form 3, March 18, 2026
Nan Wang Chief Financial Officer Form 3, March 18, 2026
Guang (Helen) Yang Chief Business Officer Form 3, March 18, 2026
Qiang (Nmn) Gao Chief Operation Officer Form 3, March 18, 2026
Jing (Nmn) Li VP, Quality and Production Form 3, March 18, 2026

What Sinovac Biotech Ltd does

We are a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with significant unmet medical needs. We have developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus..

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 71.9 million (as of December 31, 2025) 20-F, June 5, 2026
Public float $0 (as of December 31, 2011) 20-F, April 12, 2012
Reportable segments 1 (period ending December 31, 2025) 20-F, June 5, 2026
Auditor Zhonghua Certified Public Accountants LLP (Shanghai, China) Latest 10-K

Recent 8-K events

Frequently asked questions about Sinovac Biotech Ltd

What does Sinovac Biotech Ltd do?
In its own words, from Item 1 of its 10-K: "We are a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with significant unmet medical needs. We have developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus.."
What is Sinovac Biotech Ltd's revenue?
$386M for the fiscal year ending December 31, 2025, from its 20-F filed June 5, 2026.
Is Sinovac Biotech Ltd profitable?
Sinovac Biotech Ltd reported net income of -$199M for the fiscal year ending December 31, 2025.
How many employees does Sinovac Biotech Ltd have?
About 2,602 as of December 31, 2025, as stated in its annual report.
Who is the CEO of Sinovac Biotech Ltd?
Yin Weidong, Chief Executive Officer, as named in a 3 filed March 18, 2026.
Who is the CFO of Sinovac Biotech Ltd?
Nan Wang, Chief Financial Officer, as named in a 3 filed March 18, 2026.
Where is Sinovac Biotech Ltd headquartered?
Beijing, China.
What is Sinovac Biotech Ltd's stock ticker?
SVA on Nasdaq.
What industry is Sinovac Biotech Ltd in?
Pharmaceutical Preparations, SIC code 2834.
What is Sinovac Biotech Ltd's website?
sinovac.com. Investor relations: https://www.sinovac.com/en-us/Investors.
Is Sinovac Biotech Ltd a public company?
Yes. Sinovac Biotech Ltd files with the SEC under CIK 0001084201 and trades as SVA.
Who audits Sinovac Biotech Ltd?
Zhonghua Certified Public Accountants LLP, Shanghai, China, as named in its latest annual report (10-K).
How many shares of Sinovac Biotech Ltd are outstanding?
71.9 million shares as of December 31, 2025, from its 20-F filed June 5, 2026.
What is Sinovac Biotech Ltd's public float?
$0 as of December 31, 2011, as reported on the cover of its 20-F filed April 12, 2012.
How many business segments does Sinovac Biotech Ltd report?
1 reportable segment for the period ending December 31, 2025, from its 20-F filed June 5, 2026.